Unambiguous Detection of Multiple TP53 Gene Mutations in AAN-Associated Urothelial Cancer in Belgium Using Laser Capture Microdissection by Aydin, Selda et al.
Available at:
http://hdl.handle.net/2078.1/150515
[Downloaded 2019/04/19 at 11:16:13 ]
"Unambiguous Detection of Multiple TP53 Gene
Mutations in AAN-Associated Urothelial Cancer
in Belgium Using Laser Capture Microdissection"
Aydin, Selda ; Dekairelle, Anne-France ; Ambroise, Jérôme ; Durant, Jean-François ;
Heusterspreute, Michel ; Cosyns, Yves Guiot, Jean-Pierre ; Gala, Jean-Luc ; Hurst, Robert
Abstract
In the Balkan and Taiwan, the relationship between exposure to aristolochic acid
and risk of urothelial neoplasms was inferred from the A>T genetic hallmark
in TP53 gene from malignant cells. This study aimed to characterize the
TP53 mutational spectrum in urothelial cancers consecutive to Aristolochic Acid
Nephropathy in Belgium. Serial frozen tumor sections from female patients (n = 5)
exposed to aristolochic acid during weight-loss regimen were alternatively used
either for p53 immunostaining or laser microdissection. Tissue areas with at least
60% p53-positive nuclei were selected for microdissecting sections according
to p53-positive matching areas. All areas appeared to be carcinoma in situ.
After DNA extraction, mutations in the TP53 hot spot region (exons 5-8) were
identified using nested-PCR and sequencing. False-negative controls consisted
in microdissecting fresh-frozen tumor tissues both from a patient with a Li-
Fraumeni syndrome who carried a p53 constitutional mutat...
Document type : Article de périodique (Journal article)
Référence bibliographique
Aydin, Selda ; Dekairelle, Anne-France ; Ambroise, Jérôme ; Durant, Jean-François ;
Heusterspreute, Michel ; et. al. Unambiguous Detection of Multiple TP53 Gene Mutations in AAN-
Associated Urothelial Cancer in Belgium Using Laser Capture Microdissection. In: PLoS One, Vol.
9, no.9, p. e106301 (2014)
DOI : 10.1371/journal.pone.0106301
Unambiguous Detection of Multiple TP53 Gene
Mutations in AAN-Associated Urothelial Cancer in
Belgium Using Laser Capture Microdissection
Selda Aydin1, Anne-France Dekairelle2, Je´roˆme Ambroise2, Jean-Franc¸ois Durant2,
Michel Heusterspreute2, Yves Guiot1, Jean-Pierre Cosyns1., Jean-Luc Gala2*.
1Department of Pathology, Cliniques Universitaires Saint-Luc (CUSL), Universite´ Catholique de Louvain (UCL), Institut de Recherche Expe´rimentale et Clinique (IREC),
Brussels, Belgium, 2Center for Applied Molecular Technologies (CTMA), Cliniques Universitaires Saint-Luc (CUSL), Universite´ Catholique de Louvain (UCL), Institut de
Recherche Expe´rimentale et Clinique (IREC), Brussels, Belgium
Abstract
In the Balkan and Taiwan, the relationship between exposure to aristolochic acid and risk of urothelial neoplasms was
inferred from the A.T genetic hallmark in TP53 gene from malignant cells. This study aimed to characterize the TP53
mutational spectrum in urothelial cancers consecutive to Aristolochic Acid Nephropathy in Belgium. Serial frozen tumor
sections from female patients (n = 5) exposed to aristolochic acid during weight-loss regimen were alternatively used either
for p53 immunostaining or laser microdissection. Tissue areas with at least 60% p53-positive nuclei were selected for
microdissecting sections according to p53-positive matching areas. All areas appeared to be carcinoma in situ. After DNA
extraction, mutations in the TP53 hot spot region (exons 5–8) were identified using nested-PCR and sequencing. False-
negative controls consisted in microdissecting fresh-frozen tumor tissues both from a patient with a Li-Fraumeni syndrome
who carried a p53 constitutional mutation, and from KRas mutated adenocarcinomas. To rule out false-positive results
potentially generated by microdissection and nested-PCR, a phenacetin-associated urothelial carcinoma and normal fresh
ureteral tissues (n = 4) were processed with high laser power. No unexpected results being identified, molecular analysis was
pursued on malignant tissues, showing at least one mutation in all (six different mutations in two) patients, with 13/16
exonic (nonsense, 2; missense, 11) and 3/16 intronic (one splice site) mutations. They were distributed as transitions (n = 7)
or transversions (n = 9), with an equal prevalence of A.T and G.T (3/16 each). While current results are in line with A.T
prevalence previously reported in Balkan and Taiwan studies, they also demonstrate that multiple mutations in the TP53 hot
spot region and a high frequency of G.T transversion appear as a complementary signature reflecting the toxicity of a
cumulative dose of aristolochic acid ingested over a short period of time.
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Introduction
The Aristolochic Acid Nephropathy (AAN) was first reported in
the early 1990’s in Belgian patients having undertaken a weight-
loss regimen contaminated with aristolochic acid (AA) [1,2]. AAN
is characterized by a rapidly progressive interstitial nephropathy
with tubular proteinuria and glucosuria, early severe anemia,
extensive hypocellular interstitial fibrosis decreasing from the outer
to the inner cortical labyrinth, and a rapid development of urinary
tract transitional cell carcinomas in 40–46% of the patients within
2–6 years after cessation of exposure [3–6]. AAN is now
recognized as a devastating disease occurring worldwide with as
many as 100 million people potentially at risk of AA exposure [7].
While the mechanism of AA nephrotoxicity remains to be
thoroughly explored, the carcinogenic activity is currently
attributed to genotoxicity of AL (aristolactam)-DNA adducts
characterized by a high frequency of A.T transversion in the
TP53 tumour suppressor gene of AA-associated tumors. This has
been well documented in animal experiments [8,9] and, although
not consistently, in patients showing clinical and histopathological
similarities with the original Belgian AAN cases [10–14]. Whereas
AL-DNA adducts demonstrating AA exposure have been well
documented in kidney tissues from the Belgian cohort [6,15,16],
the presence of A.T transversion witnessing the causal relation-
ship between exposure and malignancy had yet to be investigated.
The aim of the present work was therefore to characterize the
TP53 mutational spectrum in frozen samples of malignant
urothelial tissues from Belgian AAN patients using thoroughly
validated genotyping methods.
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Patients and Methods
Ethics Statement
In 2001, a study on the genetic polymorphism of enzymes
implicated in the metabolism of aristolochic acid among Belgian
AAN patients was approved by Prof JM Maloteaux, Chairman of
the Faculty of Medicine and Health Sciences Research Ethics
Committee of the Universite´ catholique de Louvain (Belgium).
Following Ethics Committee approval, a written informed consent
was provided by each patient from the Belgian AAN series. These
study data remained unpublished.
In 2009, an amendment to the pilot study defined specifically
the current TP53 research which was carried out on tissue samples
from 5 AAN patients reported in this study, and was accepted as
such by the Research Ethics Committee of the Universite´
catholique de Louvain (Belgium) as a continuation of the study
started in 2001. Tissue samples from patients 1–5 which were all
part of the original study (2001) were anonymized prior to analysis.
Blood samples were part of a previous study (UCL Ethics
Committee approval reference no. 2003/05/03/08) [17]. Adeno-
carcinoma and surgical ureteric samples were collected from AA-
unrelated patients as part of their medical treatment and were
anonymized prior to analysis. After written information, adenocar-
cinoma tissues were stored in UCL Biological library (http://www.
centreducancer.be/fr/show/index/section/8/page/34). Non AA-
related ureteric samples taken from nephroureterectomies removed
at the time of renal transplantation were used as controls in this
study with a codification after pathological analysis in accordance
with the Belgian laws on tissue banking (2008).
The snap-frozen granulosa-cell tumour specimen from the Li-
Fraumeni patient was obtained from the UCL biological library
(same as above). After written consent from the parents, this
sample was anonymized prior to use.
Previous reported data include AL-DNA adducts identified in
kidney tissue from patients 1, 3, 4 [15,16,18] and TP53 gene
sequencing performed in a bladder TCC from patient 1 [10].
AAN patients
Five AAN patients referred to Cliniques Universitaires Saint-
Luc (Brussels, Belgium) were studied (Table 1). All were women
with a mean age of 42.8 years (range: 27–53) at presentation. One
patient was a smoker. None had a history of analgesic abuse or
typical features of analgesic nephropathy. They all underwent
bilateral nephroureterectomy either at the time of renal trans-
plantation or subsequently for upper urinary tract malignancies.
Besides, one patient also underwent transurethral resections of
recurrent transitional cell carcinoma (TCC) of the bladder and,
eventually, cystectomy. The diagnosis of AAN was based on the
following criteria: AA intake through a weight-loss regimen
phytochemically demonstrated as contaminated (patients 1, 2, 3
and 5), a typical renal histology of interstitial fibrosis (all five
patients), identification of AL-DNA adducts in kidney tissue
(patients 1, 3 and 4) and development of upper urinary tract
malignancy (all five patients) [15,16,18]. In patient 4, the intake of
AA could however never be formally proven as she claimed to
have attended the weight-loss clinic before the regimen contam-
inated with AA (so-called ‘‘formula 2’’) was introduced [1].
Nevertheless, all five patients fulfil the recently proposed criteria
for a definite diagnosis of AAN [19] in the current case series.
Albeit lacking the TP53 mutation status, it is worth noting that
patient 1 is nu3 in references 4, 5, 15 and 16, patient 2 is nu7 in
reference 5, patient 3 is nu4 in references 15 and 16, nu5 in
reference 5, and patient 4 is nu2 in reference 20 and number nu8
in reference 18 whereas patient 5 has not yet been reported.
Surgical specimens
Tissues from five pelvi-ureterectomies and a single cystectomy
were selected on the basis of the availability of frozen material.
Carcinoma in situ (CiS) and papillary TCC were diagnosed
accordingly to the 2004 WHO classification of urothelial tumours
[21,22]. Unilateral multifocal CiS developed in the right upper
urinary tract (pelvis, upper, mid and lower ureter) in two patients
(patient 1 and 5). While ureteral CiS invaded focally the lamina
propria in patient 1, she also developed bladder papillary TCC.
Bilateral multifocal CiS developed in the upper urinary tract of the
3 remaining patients. Delay between end of exposure and surgery
averaged 44.75 months (range 15–96) in patients 1, 2, 3, 5 and was
unavailable in patient 4. In the former four patients, unilateral and
bilateral TCC were diagnosed an average of 61 months (range:
27–96) and 41 months (range: 18–64) after end of known
exposure, respectively.
p53 immunohistochemistry (IHC)
CiS was identified by light microscopy on hematoxylin eosin
stained sections from frozen pelvi-ureteric samples. Out of serial
frozen sections (7 mm-thick), sections nu1, nu3 and nu5 were used
for p53 immunohistochemistry (IHC) and kept overnight at 37uC
whereas sections nu2, nu4 and nu6 were used for laser microdis-
section. The latter three sections were placed on biochemically
inert Polyethylene naphtalate (PEN) membrane covered slides and
kept at -20uC until use. For p53 IHC, the sections kept at 37uC
were subsequently fixed in formaldehyde 4% for 3 hours.
Endogenous peroxydase was blocked with 0.3 % hydrogen
peroxide in deionized water for 30 min. The slides were incubated
at 97uC for 75 min and rinsed in a solution containing deionized
water and triton 0.05%. The sections were then covered for
30 min with 10% normal goat serum (NGS) containing 1% bovine
serum albumin (BSA), diluted in tris-triton. They were incubated
overnight at room temperature with the anti-p53 mouse mono-
clonal antibody DO-7 (Biocarta, Europe Gmbh) at a dilution of
1:1000. After washing with tris-triton 0.05%, the slides were
incubated at room temperature for 75 min with a ready-for use
anti-mouse EnVision-Peroxidase system (Dako, Glostrup, Den-
mark) according to the manufacturer’s protocol and counter-
stained with hematoxylin. A normal goat serum was used as
negative control.
Overexpression of p53 was defined as nuclear staining
irrespective of IHC intensity. Extensive p53 staining by IHC has
previously been recommended to enhance the mutation detection
rate of TP53 [23]. Accordingly, only tissue areas containing more
than 60% of positive nuclei were selected for microdissection.
Exactly matching areas from yet unprocessed serial sections (nu2,
nu4 and nu6) underwent microdissection as detailed hereafter.
Laser capture microdissection
After toluidine blue staining, each unfixed frozen tissue area
which exactly matched the area of interest defined according to
p53 IHC slides was isolated using a PALM microlaser system
(Bernried, Germany) equipped with a pulsed UV nitrogen laser
(wavelength: 337 nm; Pulse energy.270 mJ, pulse duration 3nsec,
pulse frequency 1–30/sec) and the PALM Robot Software Version
2.2. The system was coupled to an Axiovert 200 microscope and a
Plan Neofluar 206 (Zeiss, Oberkochen, Germany). Microdissected
foci were catapulted into a microtube cap and frozen at 220uC
until DNA extraction (Figure 1).
TP53 Mutations in Belgian AAN-Associated Cancer
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e106301
T
a
b
le
1
.
C
lin
ic
al
,
p
at
h
o
lo
g
ic
al
an
d
TP
53
g
e
n
e
m
u
ta
ti
o
n
al
d
at
a
o
f
ar
e
as
w
it
h
e
xt
e
n
si
ve
p
5
3
IH
C
o
ve
re
xp
re
ss
io
n
in
T
C
C
o
f
B
e
lg
ia
n
A
A
N
p
at
ie
n
ts
.
A
A
N
P
at
ie
n
ts
(A
g
e
/S
e
x)
D
u
ra
ti
o
n
o
f
fo
rm
u
la
2
re
g
im
e
n
(m
o
n
th
)
S
m
o
ki
n
g
st
at
u
s
(p
ac
k-
ye
ar
s)
M
o
n
th
s
fr
o
m
e
n
d
o
f
A
A
e
xp
o
su
re
an
d
S
u
rg
e
ry
R
A
L
in
re
n
al
ti
ss
u
e
(m
e
an
6
S
D
/1
0
e
xp
7
n
u
cl
e
o
ti
d
e
s)
a
p
5
3
p
o
si
ti
ve
ar
e
as
an
al
ys
e
d
fo
r
T
P
5
3
m
u
ta
ti
o
n
s
Lo
ca
li
sa
ti
o
n
o
f
ti
ss
u
e
M
u
lt
if
o
ca
l
T
C
C
IH
C
In
tr
o
n
Ex
o
n
G
e
n
o
m
ic
p
o
si
ti
o
n
M
u
ta
te
d
co
d
o
n
Ef
fe
ct
o
f
th
e
m
u
ta
ti
o
n
1
(2
7
/F
)
2
0
5
1
5
(L
e
ft
N
u
x)
4
.1
6
2
.7
-
N
D
N
D
N
D
N
D
N
D
N
D
2
7
(R
ig
h
t
N
u
x)
3
.0
6
1
.8
P
e
lv
is
C
iS
N
D
N
D
N
D
N
D
N
D
N
D
1
1
1
(C
x)
*
N
D
B
la
d
d
e
r
C
iS
an
d
p
ap
ill
ar
y
+
-
7
g
.
A
1
3
3
2
5
C
T
2
3
0
P
M
is
se
n
se
g
.G
1
3
3
8
0
A
R
2
4
8
Q
M
is
se
n
se
2
(4
1
/F
)
1
5
0
5
0
(L
e
ft
N
u
x)
N
D
P
e
lv
is
C
iS
+
-
5
g
.A
1
2
4
7
8
T
K
1
6
4
X
N
o
n
se
n
se
5
3
(R
ig
h
t
N
u
x)
N
D
P
e
lv
is
C
iS
+
-
-
-
-
-
3
(4
2
/F
)
2
1
0
1
8
(R
ig
h
t
N
u
x)
2
.5
6
2
.1
U
re
te
r
C
iS
N
D
N
D
N
D
N
D
N
D
N
D
6
4
(L
e
ft
N
u
x)
N
D
P
e
lv
is
C
iS
+
7
-
g
.G
1
3
7
5
7
C
In
tr
o
n
ic
4
(5
3
/F
)
N
A
0
N
A
(B
ila
te
ra
l
N
x)
2
.9
6
2
.0
in
ri
g
h
t
co
rt
e
x
-
N
D
N
D
N
D
N
D
N
D
N
D
N
A
(R
ig
h
t
su
b
to
ta
l
U
x)
N
D
U
p
p
e
r
u
re
te
r
C
iS
N
D
N
D
N
D
N
D
N
D
N
D
N
A
(L
e
ft
U
x
an
d
re
m
n
an
t
ri
g
h
tu
U
x)
N
D
Le
ft
u
p
p
e
r
u
re
te
r
C
iS
+
-
5
g
.C
1
2
4
0
1
T
A
1
3
8
V
M
is
se
n
se
+
-
6
g
.T
1
2
7
2
2
C
V
2
1
8
A
M
is
se
n
se
Le
ft
m
id
u
re
te
r
C
iS
+
-
5
g
.G
1
2
4
6
1
T
R
1
5
8
L
M
is
se
n
se
+
6
-
g
.G
1
2
7
5
9
A
In
tr
o
n
ic
+
-
7
g
.G
1
3
3
2
3
T
C
2
2
9
F
M
is
se
n
se
Le
ft
lo
w
e
r
u
re
te
r
C
iS
+
-
8
g
.C
1
3
8
2
4
T
R
2
8
2
W
M
is
se
n
se
5
(5
1
/F
)
2
0
0
9
6
(R
ig
h
t
an
d
le
ft
u
N
u
x)
N
D
R
ig
h
t
p
e
lv
is
C
iS
+
-
6
g
.A
1
2
7
2
8
G
Y
2
2
0
C
M
is
se
n
se
8
g
.G
1
3
7
9
1
C
E2
7
1
Q
M
is
se
n
se
g
.A
1
3
8
3
7
T
E2
8
6
V
M
is
se
n
se
R
ig
h
t
m
id
u
re
te
r
C
iS
+
5
-
g
.A
1
2
6
2
7
T
D
o
n
o
r
sp
lic
e
si
te
-
6
g
.A
1
2
6
8
3
G
Y
2
0
5
C
M
is
se
n
se
-
8
g
.G
1
3
8
3
6
T
E2
8
6
X
N
o
n
se
n
se
A
b
b
re
vi
at
io
n
s:
R
A
L:
R
e
la
ti
ve
ad
d
u
ct
la
b
e
lli
n
g
,
N
x:
N
e
p
h
re
ct
o
m
y,
N
u
x:
N
e
p
h
ro
u
re
te
re
ct
o
m
y,
U
x:
U
re
te
re
ct
o
m
y,
C
x:
C
ys
te
ct
o
m
y,
N
D
:
n
o
t
d
o
n
e
,
N
A
:
n
o
t
av
ai
la
b
le
.
a
M
e
an
o
f
at
le
as
t
th
re
e
d
e
te
rm
in
at
io
n
s
in
re
p
o
rt
e
d
se
p
ar
at
e
e
xp
e
ri
m
e
n
ts
[1
5
,1
6
,1
8
].
*
M
u
ta
ti
o
n
s
p
re
vi
o
u
sl
y
re
p
o
rt
e
d
[1
0
]
an
d
co
n
fi
rm
e
d
b
y
th
e
FA
SA
Y
m
e
th
o
d
[2
5
]
in
th
e
C
e
n
te
r
fo
r
A
p
p
lie
d
M
o
le
cu
la
r
T
e
ch
n
o
lo
g
y
o
f
th
e
U
n
iv
e
rs
it
e´
C
at
h
o
liq
u
e
d
e
Lo
u
va
in
.
u
N
o
C
iS
fo
u
n
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
6
3
0
1
.t
0
0
1
TP53 Mutations in Belgian AAN-Associated Cancer
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106301
DNA extraction
In each cap, 10 ml of a solution containing EDTA 0.001 M
(pH 8), Tris HCl 0.02 M (pH 8), 0.5% Tween 20, proteinase K
(2 mg/ml) and ultrapure water was included. After mixing and
centrifugation, each reaction tube was overlaid with one drop of
mineral oil to prevent evaporation and incubated overnight at
55uC with continuous agitation (600 rpm). Ultrapure water (5 ml)
was then added to the reaction tube to increase the final volume of
the solution. After centrifugation, the solution was heated at 99uC
for 10 min to inactivate the proteinase K. Finally the extract was
transferred to another microtube.
Nested-PCR
Exons 5 to 8, corresponding to the p53 DNA binding domain, a
so-called ‘‘hot spot’’ for TP53 gene mutations [24], were amplified
by nested-PCR. For the first PCR round, 3 ml of DNA extracted
from each microdissected sample was added to a final 50 mL PCR
mix including 2.25 mM MgCl2, 0.2 U/mL Taq Gold polymerase
(Ampli Taq Gold, Applied Biosystems, Roche), 0.2 mM dNTP
and 0.2 pm/mL primers (Eurogentec, Lie`ge, Belgium) (Table 2).
An initial incubation at 95uC for 4 min was followed by 25 cycles
(95uC for 30 sec, 60uC except for exon 7 where annealing
temperature was 55uC for 30 sec and 72uC for 1 min) and a final
elongation for 7 min at 72uC. The second PCR round was carried
out with 2.5 ml of the first PCR product using the same conditions
as for the first round, except that 1.5 mM of MgCl2 and 0.4 U/mL
of Taq Gold polymerase were used for exon 6. Ultrapure water
was used as negative control whereas DNA extracted from
unrelated blood samples was used as control for TP53 amplifi-
cation.
Sequence analysis
Amplified products were purified using the MSB Spin
PCRapace kit (STRATEC Molecular GmbH, Berlin, Germany)
according to the manufacturer’s instructions. Sequence analysis
was carried out on an automated ABI 377 A apparatus (Applied
Biosystems, Foster City, CA), using the Taq Dye Deoxy
Terminator Cycle Sequencing kit from the same manufacturer
and according to its instructions. The TP53 reference sequence
from Genbank was NC_000017.10.
Assessment of potential TP53 -artifactual alterations in
tissue samples
(a) To assess the ability of the current microdissection procedure
to identify DNA mutations, four colo-rectal adenocarcinomas
previously investigated for KRas mutation by routine clinical
testing on FFPE (Formalin-fixed paraffin-embedded) tissue spec-
imens were selected. Two of them carried a mutation and two
were wild-type. These four samples were chosen because a snap-
frozen counterpart was kept stored at 270uC in the Cancer
Human Bio-bank of the Universite´ catholique de Louvain
(https://www.uclouvain.be/416846.html). Laser microdissection
and DNA extraction of snap-frozen adenocarcinoma specimens
were carried out using the procedure described above and the
results of KRas testing were compared. Additionally, a snap frozen
granulosa-cell tumour specimen from a 15 year-old young girl with
a Li-Fraumeni syndrome was analysed using the same microdis-
section procedure. While the constitutional mutation had already
been identified by FASAY (functional analysis of separated alleles
in yeast) of the TP53 mRNA extracted from peripheral
mononuclear cells of the patient [25], the tumour specimen was
studied to further confirm the ability of the current microdissection
Figure 1. Microdissection procedure of p53 overexpressing fresh frozen malignant area. A–G TCC area containing more than 60% p53
stained nuclei by IHC counterstained with hematoxylin from frozen section of ureter (A). For laser capture microdissection, a toluidine blue stained
area in a representative frozen section was matched (B), cut (C) and catapulted (D) in the cap of a microtube (E). 39-59dideoxy sequencing
electropherogram of the segment of p53 showing the wild type sequence (F, arrow) and A.T transversion (G, arrow) leading to missense mutation
E286V in exon 8.
doi:10.1371/journal.pone.0106301.g001
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procedure to identify correctly this TP53 mutation in frozen
sections of the tumour.
(b) Whether snap-frozen tissue sections could be affected by a
laser-induced effect is not known and this could even be worsened
by additional interfering factors such as a deleterious effect of the
fixation, staining and/or nested-PCR procedures. To exclude such
technological bias, surgical ureter specimens were collected after
nephroureterectomies (n = 4) taken from kidney transplanted
patients for terminal uremia due to polycystic kidney disease
(n = 2), chronic idiopathic interstitial nephritis definitely unrelated
to AA ingestion (n = 1), and diabetic glomerulosclerosis (n = 1).
These specimens were immediately embedded in Tissue-Tek and
snap-frozen, and urothelial areas were processed concomitantly in
three different ways. Microdissection was carried out under two
different intensities (low mean UV-energy: 68; and high mean
UV-energy: 69.4) and subsequently processed as reported here for
the AAN-patient samples. By comparison, additional serial
sections from the same ureter sample underwent a simple slide
scratching as carried out in KRas routine mutation testing on
FFPE tissue specimens. DNA extraction, amplification and TP53
sequencing were carried out according to the method described in
this article.
(c) As additional control of AA-unrelated TP53 artifactual
alterations potentially induced by the current analysis, a phenac-
etin-induced urothelial carcinoma which is reportedly character-
ized by the absence of A . T transversions in the TP53 gene [26]
was removed from the lower ureter of a 64 year-old female,
embedded in Tissue-Tek, snap-frozen in liquid nitrogen-cooled 2-
methylbutane (isopentane) and stored at 270uC. IHC, microdis-
section, DNA extraction and TP53 sequencing were performed
according to the methods described above.
Assessment of limit of detection for Sanger sequencing
For the limit of detection study, DNA was extracted from two
Head and Neck Squamous Cell Carcinoma cell lines (SC173 and
SC263, kindly provided by A.C. Begg, Netherlands Cancer
Institute, The Netherlands) carrying different TP53 mutations and
from a wild-type TP53 HNSCC cell line (HN30, kindly provided
by M. Flinterman, Department of Oral Medicine and Pathology,
King’s College London, The Rain Institute, UK). Characteriza-
tion of the TP53 status was previously performed in our
laboratory using FASAY analysis [25]. SC173 carries a missense
mutation in exon 5: R175H (CGC.CAC). SC263 presents a
compound heterozygous alteration involving a nonsense mutation
R306X in exon 8 (CGA.TGA) and a 32-bp deletion in exon 7
(del 704–735) (CTMA laboratory data). DNA from both TP53
mutated cells was serially diluted and spiked in the wild-type cell
DNA to have 50 to 1.25% mutant to wild-type DNA ratios.
Amplification and sequencing analysis were carried out as
described above.
Comparative statistical analysis of number and type of
mutations in current and previous data
A Poisson regression model was built to compare the prevalence
and type (A.T and G.T) of TP53 mutations in p53 binding site
between current (n = 5) and previous [BEN (n= 11 and n= 97)
and Taiwanese (n = 151)] clinical series [11,12,14], and to
compare the results of this analysis with those from patients with
urothelial malignancies (bladder, ureter, upper urinary tract and
renal pelvis) (n = 1111) as reported in the TP53 IARC database
[27]. It is worth noting that data associated with AA exposure were
discarded from TP53 IARC database results.
Results
Assessment of potential artifactual TP53 alterations in
tissue samples
Using the microdissection procedure enabled a correct identi-
fication of known DNA mutations characterized by previous
routine testing. Regarding the identification of KRas mutations on
Table 2. Primers used in the nested polymerase chain reaction.
Exons Primers Sequence (59-39) Exon Position Target size (bp) Concentration (nm)
5 E-S TGTTCACTTGTGCCCTGACTT 12334 - 21 60.7
I-S TTCAACTCTGTCTCCTTCCTCTTC 12357-… 24 128.55
E-AS AGAGCAATCAGTGAGGAATCAG 12604-… 22 60.87
I-AS AGCCCTGTCGTCTCTCCA 12563-… 18 113.69
6 E-S TTGCCCAGGGTCCCCAG 12599-… 17 78.38
I-S GGCCTCTGATTCCTCACTGA 12618-… 20 40.04
E-AS GAGGGCCACTGACAACCA 12784-… 18 77.91
I-AS TTAACCCCTCCTCCCAGAGA 12761-… 20 51.3
7 E-S GCCACAGGTCTCCCCAA 13270-… 17 72.1
I-S GCGCACTGGCCTCATCT 13288-… 17 104.67
E-AS GGTCAGCGGCAAGCAGA 13468-… 17 48.13
I-AS TGCAGGGTGGCAAGTGG 13428-… 17 102.96
8 E-S GGTTGGGAGTAGATGGAGCCT 13690-… 21 29.54
I-S TTTCCTTACTGCCTCTTGCTTCT 13743-… 23 106.47
E-AS CATTTTGAGTGTTAGACTGGAAACTTT 14097-… 27 53.77
I-AS TGAGGCATAACTGCACCCTT 13935-… 20 74.94
doi:10.1371/journal.pone.0106301.t002
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snap-frozen adenocarcinomas, results were strictly identical to
those previously obtained on FFPE samples (i.e., identification of
G12S and G12D mutations in the KRas mutated tissues and wild-
type status in the other two tumours). Regarding identification of a
constitutional g.13380 G.A, p.R248Q mutation identified by
FASAY assay in peripheral blood cells of a patient with Li-
Fraumeni syndrome, this mutation was also found in malignant
cells from the granulosa cell tumor using DNA extraction,
microdissection, nested-PCR and sequencing procedures as used
in the present study.
Conversely, no artifactual TP53 alterations were found in the
various controls carried out to test the occurrence of TP53 DNA-
induced damage related to DNA extraction, microdissection,
nested-PCR and sequencing procedures. No mutations were found
in three out of four ureter samples used to test a TP53 iatrogenic
damage. The only exception was the ureter sample from a type 2
diabetic patient with a G.A transition (g.12455, p.R156H) in
exon 5 of the TP53 gene after microdissection under high laser
power. No mutations were found in the p53 DNA binding domain
(exons 5 to 8) when analyzing DNA extracted from a phenacetin-
induced urothelial carcinoma.
Assessment of limit of detection for Sanger sequencing
The limit of detection for Sanger sequencing was identified at
6.25% of mutant to wild-type DNA ratio with both TP53 mutated
cell lines, irrespective of the mutation or deletion assessed. At this
DNA ratio, the heterozygous A/G peak with serial DNA dilutions
from SC173/HN30 mixed DNAs was still visible as also was the
heterozygous T and C peak combined with a 32-bp deletion in
exon 7 with serial DNA dilutions from SC263/HN30 mixed
DNAs.
Morphology
All p53 positive areas corresponded to papillary TCC or to CiS
containing anaplastic and dysplastic cells (Table 1). Intra-urothe-
lial and lamina propria inflammation, hyperplasia and reactive
atypia were absent. In patient 2, neoplastic and dysplastic cells
were clinging to the basement membrane (clinging CiS).
TP53 gene mutations
Including two previously reported results [10], a total of 16
totally different exonic (n = 13) or intronic (n = 3) mutations of the
TP53 gene were found in malignant urothelial tissues from the
Belgian AAN cohort (Table 1). In patient 1, two mutations were
found in the same exon (exon 7) whereas a single mutation was
found in patient 2 (exon 5) and 3 (intron 7). Patients 4 and 5
harbored 5 different exonic and 1 intronic mutations. Among the
13 exonic mutations, two were nonsense (patients 2 and 5) and 11
missense mutations (patients 1, 4 and 5). They were located in
exon 5 (3 mutations), exon 6 (3 mutations), exon 7 (3 mutations) or
exon 8 (4 mutations). One of the three intronic mutations (g.12627
A.T, patient 5) was located at the AG acceptor splice site.
Globally, mutations affected A:T pairs (7/16) and G:C pairs (9/
16). There was a nearly equal number of transitions (7/16) and
transversions (9/16). Transitions (7/16) occurred indeed with a
similar frequency at A:T pairs (3/16) and G:C pairs (4/16). A.G,
G.A and C.T (2/16) occurred with a similar frequency as T. C
(1/16). Similarly, transversions (9/16) were found at A:T pairs (4/
16) and G:C pairs (5/16) distributed as follows: A.T (3/16), G.T
(3/16), G.C (2/16) and A.C (1/16).
Comparative statistical analysis of number and type of
mutations in current and previous data
The Poisson regression model showed a highly significant (p,
0.001) relative increase of the TP53 mutation prevalence in p53
hotspot codons from the current clinical series, compared with
IARC database results (Table 3). In contrast, a significant relative
decrease was found both in the BEN (n= 97) [12] and the
Taiwanese (n = 151) [14] clinical series compared with IARC and
current clinical data (Table 3). A non-significant (p.0.05) relative
decrease/increase was found in BEN (n= 11) [11] compared with
IARC and current clinical data (Table 3).
Regarding the number of A.T transversion per patient, a
significant relative increase was found in the current, both BEN
[11,12], and the Taiwanese [14] clinical series, compared with
IARC database results (Table 4). Non-significant (p.0.05) results
were obtained when previous AAN and current clinical series were
compared (Table 4).
Compared with the IARC database results, a significant 5.85
increase of G.T prevalence was found in the current clinical
series (Table 5). No G.T transversion was found in both BEN
series. Regarding the Taiwanese series, there was a non-significant
relative decrease in G.T prevalence compared with IARC data
whereas such decrease was highly significant when compared with
current results (Table 5).
Discussion
This is the first report of the mutational spectrum of TP53
tumor suppressor gene in a series of Belgian patients (n = 5) with
documented AAN and subsequent development of TCC in the
upper urinary tract together with bladder involvement in one of
them. Four of them had followed AA-contaminated weight-loss
diet and one denied exposure to AA while presenting a typical
renal histology of interstitial fibrosis [20] with AL-DNA adducts
[18].
Using exclusively frozen samples was an absolute prerequisite to
allow adequate comparison with reported data. Except for five out
of 11 patients for whom formalin-fixed paraffin embedded tissues
were used [11], all major TP53 genetic investigations in cases
presenting with AA-induced genotoxicity and urothelial malig-
nancies were indeed led using fresh frozen tissues [11,12,14].
Conversely, the aim was to avoid the well-known deleterious effect
of formalin fixation in terms of DNA quality and characterization
of tissue mutational status [28]. To prove that TP53 mutations did
not result from technological artifacts when using frozen section, a
special attention was paid to thorough validation procedures. The
current TP53 testing included successive steps (i.e., laser capture
microdissection of tumor cells after toluidine blue staining, DNA
extraction, nested-PCR amplification and sequencing). This
method did not produce false-negative results. It enabled indeed
a correct identification of known KRas oncogenic mutations in
adenocarcinomas. It also enabled a correct identification of a
previously characterized TP53 constitutional mutation associated
with a Li-Fraumeni syndrome. This mutation was found in tumor
cells whereas the previous characterization was carried out by a
functional assay on peripheral mononuclear cells.
Likewise, the current procedure did not create false-positive
results when analyzing normal ureter specimens collected after
nephroureterectomy in patients with AA-unrelated diseases or a
phenacetin-induced carcinoma, and taking current conventional
genotyping as gold standard. This also applied when performing
laser capture microdissection with high intensity. The sole
mutation found was a single G.A transition (g.12455,
p.R156H) in the tissue specimen from a type 2 diabetic patient
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without any history of neoplasia. Of interest, there is no significant
difference in the prevalence of G.A transition between the
general population and type 2 diabetic patients [29]. As assessed
by serial dilutions of TP53 mutated DNA, the detection limit of
the current genotyping procedure was 6.25% of mutant to wild-
type ratio.
Of interest, all patients from the current series were women and
each of them presented at least one TP53 mutation in their
malignant urothelial tissues whereas a more balanced male/female
ratio was found (53%/47%) in previous studies [11,14]. In
previous studies, the reported prevalence of patients with TP53
hotspot mutation varied from 100% (11/11 BEN patients) [11] to
37% (36/97 BEN tumors) [12] or 47% (71/151) Taiwanese AA-
patients [14]. Considering that only a single patient was reported
with a quintuple mutation in the IARC database, the current
observation that 40% (2/5) of the patients harbored multiple
TP53 mutations, each with six distinct mutations (five exonic and
one intronic mutations, among which one splice site mutation in
patient 5) was a striking and very unusual finding. It is also
interesting to note that this quintuple mutation was also found in
the BEN series [12] which is one of the hitherto largest reported
human series of AA related TP53 mutations. Compared to data
from non AA-related urothelial cancers in the IARC database
(n = 1111) and from the Taiwanese series (n = 151), the current
series showed the highest relative increased prevalence of mutation
and G.T transversion in the TP53 hotspot region. Irrespective of
the current or previous AA-series, the prevalence of A.T
transversion was significantly and consistently higher than in the
IARC database [27]. Our finding confirms that the number and
profile of TP53 mutations per patient is highly unusual, probably
reflecting a sudden highly toxic exposure. Whether these multiple
mutations occurred in different malignant clones was not assessed.
However, the number of distinct tumor areas associated with this
complex mutational spectrum certainly reflects wide within-tumor
heterogeneity with poly- or multiclonal malignant urothelial cells.
Looking into details of the type of hotspot mutation in this
study, point mutations at A:T pairs were as frequent as those at
G:C pairs (7/16 versus 9/16, respectively). They were dominated
by transversions with A.T and G.T accounting each for 18.7%
(3/16) of all TP53 mutations. Interestingly, A.T transversion in
human AA-related urothelial tumour was first reported in a UK
patient [30] but A.T transversion was then frequently found in
the p53 hotspot region from urothelial carcinoma associated with
the Balkan endemic nephropathy (BEN) [11,12], as well as in
Taiwan [14]. In all these studies, the population was exposed to
AA for many years, with figures as high as 66% (33/50) to 72%
(13/18) and 55% (46/84) of all TP53 mutations, respectively. In
the current series, one tumour with multiple TP53 mutations
harbored two A.T transversions, a feature also commonly
reported in the BEN and Taiwanese series [11,12,14]. Animal
studies further confirmed the high frequency of A.T transversions
in AA-induced tumours, for instance in the forestomach epider-
moid neoplastic cells from AA-exposed rats at codon 61 of the Ha-
ras proto-oncogene [8], as well as in human p53 knock-in (Hupki)
mouse embryonic fibroblasts exposed to AAI (Aristolochic Acid I)
[31,32]. Altogether, these findings strengthen the hypothesis that
A.T transversion is both a specific alteration occurring after
experimental exposure to AA in animals, and the hallmark of AA-
exposure in humans. Accordingly, this genetic alteration appears
to be one of the main mechanisms of carcinogenesis initiated by
DNA polymerase-mediated incorporation of deoxyadenosine
monophosphate (dAMP) opposite adenine adducts [33].
In addition, a high frequency of G.T transversions was also
observed in the current series. The prevalence of G.T
transversion is usually associated with tobacco exposure as
evidenced in the Hupki mouse embryonic fibroblasts exposed to
the prominent tobacco-derived carcinogen benzo[a]pyrene [34],
as well as in smoking-related human lung cancers [35]. However,
G.T transversions are rarely identified (4%) in animal models of
AA intoxication [36], and are only occasional in Hupki mouse
embryonic fibroblasts exposed to AA [31,32]. In line with these
observations, the prevalence of G.T transversion in AA-
associated human urothelial cancers in Taiwan is low (12%) and
found in none of both BEN series [11,12,14]. In the current series
comprising only female patients, the statistically significant higher
frequency of non-smoking associated G.T transversions com-
pared with IARC database and other AAN clinical series
[11,12,14], and the unusual occurrence of two G.T transversions
in the same sample were therefore extremely unusual findings.
They may well be consistent with the reported covalent binding of
AA to d-guanosine in rodents [9] as well as in AAN patients
[6,11,13,16].
Consequently, this unusually high G.T frequency in the TP53
hot spot region has to be considered at the light of major
Table 3. Relative increased/decreased prevalence of mutation.
Reference database Compared database
BEN (n=11) [11] BEN (n=97) [12] Taiwan (n =151) [14] BELGIAN (n=5)
IARC (n =1111) 1.54 [0.98–2.42], p = 0.062 0.46 [0.35–0.61], p,0.001 0.50 [0.40–0.62], p,0.001 2.85 [1.74–4.67], p,0.001
BELGIAN (n=5) 0.54 [0.28–1.05], p = 0.069 0.16 [0.09–0.28], p,0.001 0.17 [ 0.10–0.30], p,0.001
doi:10.1371/journal.pone.0106301.t003
Table 4. Relative increased/decreased prevalence of A.T mutation.
Reference database Compared database
BEN (n=11) [11] BEN (n=97) [12] Taiwan (n=151) [14] BELGIAN (n=5)
IARC (n =1111) 40.40 [21.74–75.09], p,0.001 10.80 [6.71–17.38], p,0.001 9.67 [6.23–15.01], p,0.001 19.05 [5.86–61.93], p,0.001
BELGIAN (n=5) 2.12 [0.61–7.38], p = 0.23 0.57 [0.17–1.85], p = 0.34 0.51 [0.16–1.63], p = 0.26
doi:10.1371/journal.pone.0106301.t004
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differences between previous studies [11,12,14] and the current
work. Firstly, a limited number of patients (n = 5) was assessed in
this study compared with previous studies which included 11 to
,100 patients exposed to AA. Secondly, male and female patients
were almost equally distributed in BEN and Taiwanese cohorts
whereas the current cohort consisted only of women. Furthermore,
there were substantial differences between both former and
current cohorts in terms of mean age (66 versus 43 years old,
respectively), and exposure duration and intensity. For the latter
two features, no precise data could unfortunately be retrieved from
the Taiwanese series as patient exposure resulted from intermittent
ingestion of herbal remedies containing or likely to contain AA
[14,37]. In contrast, repeated intake of contaminated bread over
time was estimated to expose BEN patients to a toxic dietary
exposure which is equivalent to that documented for Belgian
patients with AAN [11,38]. While cumulative doses are a known
significant risk factor for developing urothelial carcinoma [6],
repeated AA exposure over a short period of time (mean 19
months) in the Belgian series may already have led to the
cumulative toxic dose which, comparatively, was only achieved
after several decades in BEN patients. Considering the higher daily
intake of AA in Belgian compared to the BEN series and the
susceptibility of hotspot codons to carcinogen-induced alterations,
differences in the mutation profile would not be surprising. One of
the major phenotypic difference observed in the Belgian cohort
was the substantially quicker development of nephrotoxicity
(within few months) and of cancer (within 2–6 years) after
cessation of AA exposure [10]. Additional differences between
studies laid in the current methodology for TP53 genotyping. This
was indeed carried out only on fresh tissues using tissue
microdissection followed by nested-PCR and conventional se-
quencing, which differs significantly from the AmpliChip p53
microarray on fresh [11,12,14] and on few formalin-fixed tissues
[11] as previously reported. In that respect, it is interesting to note
that the spectrum of TP53 genetic alterations in Taiwan and BEN
patients whom tumors were assessed using identical TP53
genotyping, was notably similar [11,12,14].
In conclusion, our documentation of expected A . T
transversions attributable to AA exposure in the TP53 gene of
the Belgian AAN associated TCC is the first demonstration of a
clear causal relationship between AA exposure and the develop-
ment of urothelial malignancy in this cohort. Interestingly, and
although assessed on small series of female patients, there are two
striking highly significant observations characterizing the current
series: the addition of poly- or multiclonal TP53 alterations to the
otherwise well-known AA mutational fingerprint and the unusu-
ally high prevalence of G.T transversion in the p53 binding site,
two new features appearing as a complementary signature possibly
reflecting the toxicity of a cumulative dose of AA over a short
period of time.
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